Table 4.
Multivariate analysis of pCR and MPR for neoadjuvant chemotherapy or combined with immunotherapy group
| Characteristic | Multivariate for pCR and MPR in neoadjuvant chemotherapy combined with immunotherapy group | Multivariate for pCR and MPR in neoadjuvant chemotherapy group | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| p-value for pCR | Odds ratio (95% CI) | p-value for MPR | Odds ratio (95% CI) | p-value for pCR | Odds ratio (95% CI) | p-value for MPR | Odds ratio (95% CI) | |
| Histology | 0.654 | - | 0.313 | - | - | - | - | - |
|
| ||||||||
| Squamous cell carcinomas | 0.820 | 0.839 (0.185–3.809) | 0.334 | 0.375 (0.051–2.744) | - | - | - | - |
|
| ||||||||
| Adenocarcinoma | 0.531 | 1.851 (0.270–12.697) | 0.710 | 1.522 (0.166–13.960) | - | - | - | - |
|
| ||||||||
| Others | 1 | 1 | ||||||
|
| ||||||||
| N (N0 or N1–2) | 0.033 | 11.741 (1.212–11.371) | 0.013 | 26.385 (1.980–35.163) | 0.278 | 0.275 (0.027–2.830) | 0.129 | 0.271 (0.050–1.460) |
|
| ||||||||
| Baseline CEA (normal or high) | 0.333 | 1.908 (0.516–7.052) | 0.834 | 1.172 (0.267–5.144) | - | - | - | - |
|
| ||||||||
| Baseline NLR (normal or high) | 0.030 | 5.407 (1.178–24.825) | 0.015 | 10.549 (1.562–72.924) | 0.095 | 7.774 (0.700–8.628) | 0.318 | 3.284 (0.319–33.795) |
|
| ||||||||
| Preoperative NLR (normal or high) | 0.546 | 1.520 (0.391–5.916) | 0.876 | 1.130 (0.190–4.119) | 0.264 | 2.979 (0.439–20.192) | 0.109 | 3.223 (0.770–13.480) |
CEA, carcinoembryonic antigen; CI, confidence interval; MPR, major pathologic response; NLR, neutrophil-to-lymphocyte ratio; pCR, pathological complete response.